[On behalf and the extent of evidence].
Ruiz
Juan
J
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002995:Clofibric Acid / Q000627:therapeutic use; D003327:Coronary Disease / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D017211:Treatment Failure
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002995:Clofibric Acid